Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Stine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Jesper Ryg, Pia Osterlund, Åke Berglund, Camilla Qvortrup, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

1 Citation (Scopus)
OriginalsprogEngelsk
TidsskriftThe Lancet Gastroenterology & Hepatology
Vol/bind4
Udgave nummer5
Sider (fra-til)376-388
Antal sider13
ISSN2468-1253
DOI
StatusUdgivet - maj 2019

Fingerprint

oxaliplatin
Combination Drug Therapy
Colorectal Neoplasms
irinotecan
Therapeutics
Disease-Free Survival

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

Citer dette

Winther, Stine Braendegaard ; Liposits, Gabor ; Skuladottir, Halla ; Hofsli, Eva ; Shah, Carl-Henrik ; Poulsen, Laurids Østergaard ; Ryg, Jesper ; Osterlund, Pia ; Berglund, Åke ; Qvortrup, Camilla ; Glimelius, Bengt ; Sorbye, Halfdan ; Pfeiffer, Per. / Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial. I: The Lancet Gastroenterology & Hepatology. 2019 ; Bind 4, Nr. 5. s. 376-388.
@article{956814e403014a468c1c90f5404fbbc6,
title = "Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial",
author = "Winther, {Stine Braendegaard} and Gabor Liposits and Halla Skuladottir and Eva Hofsli and Carl-Henrik Shah and Poulsen, {Laurids {\O}stergaard} and Jesper Ryg and Pia Osterlund and {\AA}ke Berglund and Camilla Qvortrup and Bengt Glimelius and Halfdan Sorbye and Per Pfeiffer",
note = "Copyright {\circledC} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "5",
doi = "10.1016/S2468-1253(19)30041-X",
language = "English",
volume = "4",
pages = "376--388",
journal = "The Lancet Gastroenterology & Hepatology",
issn = "2468-1253",
publisher = "Elsevier",
number = "5",

}

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial. / Winther, Stine Braendegaard; Liposits, Gabor; Skuladottir, Halla; Hofsli, Eva; Shah, Carl-Henrik; Poulsen, Laurids Østergaard; Ryg, Jesper; Osterlund, Pia; Berglund, Åke; Qvortrup, Camilla; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per.

I: The Lancet Gastroenterology & Hepatology, Bind 4, Nr. 5, 05.2019, s. 376-388.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9)

T2 - a randomised, open-label phase 2 trial

AU - Winther, Stine Braendegaard

AU - Liposits, Gabor

AU - Skuladottir, Halla

AU - Hofsli, Eva

AU - Shah, Carl-Henrik

AU - Poulsen, Laurids Østergaard

AU - Ryg, Jesper

AU - Osterlund, Pia

AU - Berglund, Åke

AU - Qvortrup, Camilla

AU - Glimelius, Bengt

AU - Sorbye, Halfdan

AU - Pfeiffer, Per

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/5

Y1 - 2019/5

U2 - 10.1016/S2468-1253(19)30041-X

DO - 10.1016/S2468-1253(19)30041-X

M3 - Journal article

VL - 4

SP - 376

EP - 388

JO - The Lancet Gastroenterology & Hepatology

JF - The Lancet Gastroenterology & Hepatology

SN - 2468-1253

IS - 5

ER -